Ascendis Pharma A/S
NASDAQ:ASND
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
90.62
159.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Ascendis Pharma A/S
Ascendis Pharma A/S
Gross Profit
Ascendis Pharma A/S
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Gross Profit
€271.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Gross Profit
kr18.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Gross Profit
kr55.4m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Gross Profit
kr3.5B
|
CAGR 3-Years
91%
|
CAGR 5-Years
62%
|
CAGR 10-Years
19%
|
|
|
F
|
Fluoguide AS
STO:FLUO
|
Gross Profit
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Gross Profit
kr24.1m
|
CAGR 3-Years
19%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
Ascendis Pharma A/S
Glance View
Ascendis Pharma A/S is a biopharmaceutical company that is dedicated to transforming the lives of patients through innovative therapies, particularly in the areas of endocrine diseases, oncology, and rare diseases. Founded in 2006 and based in Copenhagen, Denmark, Ascendis has developed a unique platform called TransCon technology, which enables the creation of new medicines that enhance the therapeutic potential of existing drugs. This innovative approach is designed to improve dosing regimens and reduce side effects, positioning Ascendis as a game-changer in the pharmaceutical landscape. With a robust pipeline, including its lead product candidate, TransCon Growth Hormone, currently in late-stage development for growth hormone deficiency, the company is strategically positioned to capture significant market potential. For investors, Ascendis Pharma represents an enticing opportunity within the biopharmaceutical sector, particularly as it navigates pivotal clinical trials and potential regulatory approvals. The company boasts a strong financial foundation, having secured substantial funding from partnerships and public offerings to support its clinical programs. With a growing emphasis on long-term value creation derived from its innovative approach to drug development, Ascendis aims to become a key player in addressing unmet medical needs. As it advances its pipeline and explores partnerships with larger pharmaceutical companies, beckoning the prospects of lucrative collaborations, investors have a chance to become involved in the journey of a company poised at the intersection of science and patient care.
See Also
What is Ascendis Pharma A/S's Gross Profit?
Gross Profit
271.7m
EUR
Based on the financial report for Jun 30, 2024, Ascendis Pharma A/S's Gross Profit amounts to 271.7m EUR.
What is Ascendis Pharma A/S's Gross Profit growth rate?
Gross Profit CAGR 1Y
187%
Over the last year, the Gross Profit growth was 187%.
You don't have any saved screeners yet
